Core Viewpoint - Venus Concept Inc. has announced its decision to voluntarily delist its common stock from the NASDAQ Capital Market and deregister its common stock with the SEC, citing that the costs of compliance outweigh the benefits for the company and its shareholders [1][2]. Delisting and Deregistration - The company is compliant with Nasdaq listing requirements but has determined that the resources needed for SEC reporting obligations are excessive compared to the benefits [2]. - Venus Concept has notified Nasdaq of its intent to delist and deregister, planning to file a Form 25 on or about January 30, 2026, with the last trading day expected to be around February 6, 2026 [3]. - A Form 15 will be filed on or about February 9, 2026, which will suspend the company's obligation to file periodic reports with the SEC [3]. Management's Perspective - The Board of Directors believes that this decision is in the best interests of the company and its shareholders, as it will reduce compliance costs and support the execution of the company's turnaround plan [4]. - The CEO of Venus Concept emphasized the collaboration with Madryn Asset Management to position the company for long-term financial success [4]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products, reaching over 60 countries [5]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [5].

Core Viewpoint - Venus Concept Inc. has successfully reduced its outstanding debt by exchanging $11.48 million of subordinated convertible notes for preferred stock, improving its financial position significantly [1][2]. Financial Position - The total debt obligations of Venus Concept are now approximately $30.1 million, reflecting a 24% reduction from $39.7 million as of December 31, 2024 [1]. Strategic Initiatives - The debt-to-equity exchange is part of Venus Concept's strategy to enhance financial flexibility and support long-term growth and profitability [2]. - The partnership with Madryn Asset Management is viewed as invaluable in advancing the company's transformation plan [2]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [4]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [4].

Core Points - Venus Concept Inc. has announced a registered direct offering of 434,720 shares of common stock at a price of $2.65 per share, with expected gross proceeds of approximately $1.15 million [1][3] - The company will also issue unregistered short-term warrants to purchase up to 869,440 shares at the same exercise price, potentially generating an additional $2.3 million if fully exercised [1][3] - The offering is expected to close around June 9, 2025, pending customary closing conditions [1] Offering Details - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The shares are being offered under a "shelf" registration statement effective since November 1, 2024, and a final prospectus supplement will be filed with the SEC [4] - The unregistered short-term warrants are offered in a private placement and have not been registered under the Securities Act [5] Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a range of minimally invasive and non-invasive products across over 60 countries [7] - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare growth equity investors [7]

Core Viewpoint - Venus Concept Inc. has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd for $20 million in cash, which is expected to enhance the company's financial condition and support strategic growth initiatives [1][2][3] Group 1: Transaction Details - The transaction is valued at $20 million, subject to customary working capital adjustments [1] - The sale includes the portfolio of hair restoration and hair transplant technologies, related equipment, services, and intellectual property, specifically for ARTAS and NeoGraft [2][3] - The transaction is anticipated to close in the third quarter of 2025, pending certain closing conditions [3] Group 2: Financial Impact - The revenue from the sale of ARTAS and NeoGraft systems, procedure kits, and warranty revenue was approximately $12.5 million in fiscal year 2024 [3] - Cash used in operations related to the hair restoration and transplant businesses totaled approximately $6.7 million in fiscal year 2024 [3] Group 3: Strategic Rationale - The CEO of Venus Concept stated that the transaction allows the company to focus on its global medical aesthetics business, which is expected to improve revenue growth and lower operating expenses [2] - Meta Healthcare Group aims to leverage the acquired technologies to expand its hair loss-related business areas and enhance R&D and manufacturing capabilities [2][5]